The Hematologic Malignancies and Cellular Therapy (HMCT) Program is a multidisciplinary basic, translational and clinical research effort whose overall goal is to improve outcomes for patients with hematologic malignancies. The broad, long-term goal of the HMCT Program is to build on and extend the current knowledge in the fields of leukemia, lymphoma, myeloma, hematopoietic cell transplantation, and immunotherapy, and to develop and implement novel strategies for improving therapeutic results in these patients through a collaborative and integrated approach involving all the investigators in the Program.
There are several areas of research. Broadly, these can be divided into: a) basic research into the tumor microenvironment, bone marrow niche, b) basic understanding of immunity, both inate and adaptive, c) genomics, including a genomics core, d) cellular therapies such as hematopoietic stem cells, adotive immunotherapy with selected T cells, NK cells, dendritic cell vaccines, gamma delta T cells, e) graft-versus-host disease and graft-versus-leukemia effects, and f) cell signaling pathways in normal and tumor cells. As a complement to these efforts, there is also a robust clinical trials office with over 100 active clinical trials specific to hematologic malignancies and transplantation. These range from phase I “first in humans” to randomized phase III studies.
To make an appointment, please call 919.684.8964 for Hematologic Malignancies or 919.668.1027 for Adult Bone Marrow Transplant.
For more information on blood cancer care at Duke Health, visit:
To find a doctor, visit Find A Specialist.
Having and surviving Hodgkin Lymphoma at a young age influenced the career path of Sasha Zabavin, the director of annual giving at Caring House, and changed the way the 26-year-old sees her future. Colleagues say her story is very motivating for staff and guests. More
Duke Cancer Institute constellates the world-class resources of Duke University, Duke Health and the Duke Comprehensive Cancer Center into a collaborative powerhouse. We are poised to drive a paradigm shift in the way long-established cancer centers and institutes have been waging this war.Learn More